Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened
Thomas Edward Schoenherr, CEO of diagnostics at Tempus AI (NASDAQ: TEM), sold 17,314 shares of Class A Common Stock across August 18 and 19 for approximately $930,000. These sales were part of a pre-established Rule 10b5-1 trading plan to cover tax withholding obligations from restricted stock unit vesting, not a discretionary move after the stock's recent volatility. Schoenherr retains a significant stake, and the company emphasized that the scheduled sale during a volatile week should not deter long-term investors from focusing on performance.
Tempus AI EVP, chief legal officer Polovin sells $1.54m in stock
Andrew Polovin, EVP and Chief Legal Officer of Tempus AI (NASDAQ:TEM), sold 30,075 shares totaling approximately $1.54 million across two transactions on August 18 and 19, 2026. One sale was to cover tax obligations from vested restricted stock units, while the other was part of a pre-planned trading strategy. These sales occurred as Tempus AI stock surged 28% over the prior week, leading to concerns about overvaluation, and follow the company's recent Q2 2026 financial results which saw a narrower loss but a revenue miss.
Tempus AI diagnostics CEO sells nearly $930k in stock
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI, recently sold 17,314 shares of the company's Class A Common Stock for approximately $929,989. These sales occurred on August 18 and 19, 2026, amid a 28% stock surge. One transaction was for tax withholding, while the other was executed under a Rule 10b5-1 trading plan.
Tempus AI CFO James Rogers sells $2.69m in stock
Tempus AI's CFO, James Rogers, sold approximately $2.69 million worth of Class A Common Stock in mid-August through two transactions. One sale covered tax withholding obligations, while the other was part of a Rule 10b5-1 trading plan. These sales occurred as the stock surged 28% and is considered overvalued by InvestingPro.
Tempus AI chief accounting officer sells $306,341 in shares
Tempus AI's Chief Accounting Officer, Ryan M. Bartolucci, sold 6,175 shares worth $306,341 to cover tax withholding obligations. This sale occurred on August 18, 2026, and was not a discretionary transaction. The company's stock has since risen significantly, despite recent mixed financial results and revised price targets from analysts.
Tempus AI (NASDAQ: TEM) CAO sells shares in tax-cover move
Tempus AI (NASDAQ: TEM) Chief Accounting Officer Ryan M. Bartolucci sold 6,175 shares of Class A Common Stock on August 18, 2026, at a weighted average price of $49.61 per share. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations upon the vesting of restricted stock units, not a discretionary sale. After the sale, Bartolucci directly holds 67,866 shares of Tempus AI Class A Common Stock.
Tempus AI, Inc. Class A Revenue Breakdown – FWB:F3M
Tempus AI, Inc. (FWB:F3M) generated 1.08 billion EUR in revenue last year, with its Genomics segment being the top performer, contributing 813.43 million EUR. The United States was the primary geographic contributor, accounting for the entire 1.08 billion EUR in revenue.
Tempus AI (TEM) CEO offloads shares to cover RSU taxes owed
Tempus AI (TEM) CEO and Chairman Eric P. Lefkofsky sold 132,591 shares of Class A Common Stock on August 18, 2026, at a weighted average price of $49.61 per share. This sale was mandated to cover statutory tax withholding obligations from RSU vesting and was not a discretionary transaction. Following the sale, Lefkofsky retains significant direct and indirect holdings in the company.
Tempus AI (TEM) legal chief sells 30K shares via tax cover and 10b5-1 plan
Tempus AI's EVP and Chief Legal Officer, Andrew Polovin, sold a total of 30,075 shares of Class A Common Stock across two transactions in August 2026. The sales included 22,148 shares to cover tax withholdings on vested restricted stock units and 7,927 shares under a Rule 10b5-1 trading plan. The transactions totaled approximately $1.54 million.
Tempus AI (TEM) CFO unloads 48,842 shares via tax cover and plan
Tempus AI (TEM) CFO James William Rogers sold a total of 48,842 shares of Class A Common Stock across two days in August 2026. This included 22,529 shares sold to cover statutory tax withholding obligations on RSU vesting, and 26,313 shares sold under a pre-arranged Rule 10b5-1 trading plan. These sales are detailed in a Form 4 SEC filing, with specific prices and dates for each transaction.
Tempus AI (TEM) insider's tax sale and remaining stake
Tempus AI (TEM) officer Ryan Fukushima sold 41,095 shares of Class A Common Stock for $49.61 per share on August 18, 2026. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations from restricted stock unit vesting and was not a discretionary sale. Following this, Fukushima directly holds 562,463 shares and indirectly holds 61,706 shares through his spouse.
Tempus AI (TEM) exec’s 17K share sale blends taxes and 10b5-1 plan
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI (TEM), sold a total of 17,314 shares of Class A Common Stock across seven transactions on August 18-19, 2026. A block of 9,232 shares was sold to cover tax withholding obligations upon the vesting of restricted stock units, which was not a discretionary sale. The remaining sales were executed under a Rule 10b5-1 trading plan established on March 3, 2026.
Ryan Fukushima, CEO, sells $2.04m in Tempus AI stock
Tempus AI CEO Ryan Fukushima sold 41,095 shares of Class A Common Stock for approximately $2.04 million on August 18, 2026. This transaction was a "sell to cover" for tax obligations related to restricted stock units, not a discretionary sale. The stock has since seen a significant surge, and the company recently reported Q2 2026 revenue growth and ongoing strategic developments including acquisitions and analyst rating adjustments.
Tempus AI Inc Stock (TEM) Moved Up by 10.87% on Aug 20: What Signal Does It Send?
Tempus AI Inc (TEM) saw its stock rise by 10.87% on August 20, driven by positive Phase 3 trial results for individualized mRNA cancer vaccines from Merck and Moderna, which validated Tempus AI's acquisition of Personalis. The stock also benefited from a reaffirmed Buy rating and raised price target from BTIG Research, strong quarterly earnings, and a short squeeze due to elevated short interest. However, the company faces risks such as equity dilution from the Personalis acquisition, insider stock liquidation, negative free cash flow, and analyst valuation caps.
Tempus AI (TEM) exec's $2.1M stock sale tied to tax withholding
Tempus AI (TEM) officer Ryan Fukushima has filed a Rule 144 notice for the potential sale of 41,095 shares of Class A common stock, valued at approximately $2.1 million. The company clarified that this sale is a mandatory "sell to cover" transaction to satisfy tax withholding obligations under its equity incentive plan, not a discretionary trade. The filing also notes previous 10b5-1 sales by another participant, Vanessa Kubo.
Tempus AI (NASDAQ: TEM) plans 22,148-share sell-to-cover trade in August 2026
Tempus AI officer Andrew Polovin has filed a Rule 144 notice to sell 22,148 shares of Class A common stock through Morgan Stanley Smith Barney LLC Executive Financial Services around August 18, 2026. These sales are mandated by the company's equity incentive plan to satisfy tax withholding obligations related to various restricted stock units and performance stock units granted between 2022 and 2025. This is a sell-to-cover transaction and does not represent a discretionary trade by Polovin.
Tempus AI (NASDAQ: TEM) officer readies another tax-cover sale
Tempus AI officer James William Rogers plans to sell 22,529 Class A common shares worth an estimated $1.16 million through a Rule 144 tax-cover sale. This sale, intended to cover tax withholding obligations from restricted and performance stock units, is not a discretionary trade. Rogers previously sold 11,529 shares for $634,095 on June 25, 2026.
Tempus AI (NASDAQ: TEM) insider plans tax-cover share sale
Eric Paul Lefkofsky, an insider at Tempus AI (NASDAQ: TEM), has filed a Rule 144 notice to sell 132,591 Class A common shares valued at approximately $6.8 million. These sales are described as mandated "sell-to-cover" transactions to satisfy tax withholding obligations related to restricted and performance stock units, not discretionary trades. The filing also reports previous share sales by entities associated with Lefkofsky.
Tempus AI (NASDAQ: TEM) flags 9,232-share sale to cover taxes
An officer at Tempus AI (NASDAQ: TEM), Thomas Edward Schoenherr, plans to sell 9,232 shares of Class A Common Stock, valued at approximately $476,740.48, through Morgan Stanley Smith Barney LLC on August 18, 2026. This sale is a mandated "sell to cover" transaction to fulfill tax withholding obligations arising from vested Restricted Stock Units and Performance Stock Units, rather than a discretionary trade. The shares represent a small fraction of the 175,390,967 Class A Common Shares outstanding.
Tempus AI (TEM) director share sale under 10b5-1 plan
Tempus AI (TEM) director Nadja West reported selling 3,000 shares of Class A Common Stock on August 14, 2026, at a price of $53.90 per share. This transaction, valued at $162,000, was executed under a Rule 10b5-1 trading plan adopted on May 15, 2026. Following the sale, Nadja West directly holds 34,981 shares of Tempus AI.
Tempus AI (TEM) CEO, Data, discloses 62,239-share bona fide stock gift
Tempus AI (TEM) CEO, Data, Fukushima Ryan, reported a bona fide gift of 62,239 shares of Class A Common Stock through his spouse on August 12, 2026, with no consideration. Following this transaction, his indirect holdings via his spouse are 61,706 shares, and his direct holdings are 603,558 shares. The filing specifies this as a genuine gift, not a sale or purchase, and the Rule 10b5-1 checkbox was not affirmed.
Tempus AI CEO, data Ryan Fukushima sells $1,000,800 in shares
Tempus AI's CEO of Data, Ryan Fukushima, sold 20,000 shares of the company's Class A Common Stock for over $1 million on August 7, 2026, at an average price of $50.04 per share. This sale was conducted under a Rule 10b5-1 trading plan. The article also notes that Tempus AI's stock has since risen and highlights recent financial results and analyst ratings.
Tempus AI (TEM) executive’s spouse sells 20,000 shares under 10b5-1 plan
Tempus AI (TEM) CEO, Data, Fukushima Ryan's spouse sold 20,000 shares of Class A Common Stock on August 7, 2026, for a weighted average price of $50.04 per share. This transaction was executed under a Rule 10b5-1 trading plan adopted on March 12, 2026. After the sale, the spouse indirectly holds 123,945 shares, and Fukushima Ryan directly holds 603,558 shares.
Tempus AI, Inc. (TEM) stock price, news, quote and history
This article provides comprehensive financial information for Tempus AI, Inc. (TEM), including its current stock price, trading activity, historical data, and company overview. It details Tempus AI's healthcare technology offerings, strategic collaborations, and financial performance metrics like revenue, earnings, and analyst price targets. The report also includes comparisons with similar companies in the Health Information Services sector.
Piper Sandler Keeps Their Hold Rating on Tempus AI, Inc. Class A (TEM)
Piper Sandler reiterated a Hold rating on Tempus AI, Inc. Class A (TEM) with a price target of $56.00, according to analyst David Westenberg. This follows Tempus AI's latest earnings report showing quarterly revenue of $382.49 million and a net profit of $5.64 million, an increase from the previous year. Other analysts have also issued ratings, with Bank of America Securities maintaining a Hold and H.C. Wainwright reiterating a Buy.
Tempus AI, Inc. (TEM) director sells 370 shares under 10b5-1 plan
Tempus AI, Inc. director David R. Epstein sold 370 shares of Class A Common Stock on August 3, 2026, at a price of $43.40 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on August 27, 2024. Following this transaction, Epstein directly holds 31,094 shares. The filing indicates a neutral impact and negative sentiment for the company.
Tempus AI, Inc. (TEM) CEO's spouse sells 23,818 shares in plan
The spouse of Ryan Fukushima, CEO of Data at Tempus AI, Inc. (TEM), sold 23,818 shares of Class A Common Stock on August 3, 2026. These sales were conducted under a Rule 10b5-1 trading plan at weighted-average prices between $43.25 and $46.94. Following these transactions, Ryan Fukushima directly holds 603,558 shares.
Tempus AI model trained on 2.3M slides predicts patient outcomes
Tempus AI announced that its multimodal slide-level pathology foundation model, PRISM2, has demonstrated best-in-class performance in diagnostic and prognostic applications for cancer. Published in Nature Medicine, the study highlights PRISM2's ability to predict biomarker status and patient outcomes, including colorectal cancer recurrence-free survival, leveraging a dataset of 2.3 million whole-slide images and 14 million diagnostic question-answer pairs. The model is publicly available for research use.
Tempus AI (TEM) awards 40,000 RSUs to EVP and Chief Legal Officer
Tempus AI (TEM) reported that its EVP and Chief Legal Officer, Andrew Polovin, was granted 40,000 restricted stock units (RSUs) of Class A Common Stock on July 29, 2026. The RSUs will vest in eight equal quarterly installments starting October 29, 2026, bringing his total direct holdings to 168,215 shares after this transaction. This grant is an equity compensation award and not an open-market purchase.
Tempus AI, Inc. (TEM) awards 40,000 RSUs to CFO James Rogers
Tempus AI, Inc. (TEM) has granted 40,000 restricted stock units (RSUs) to its Chief Financial Officer, James William Rogers, on July 29, 2026. These RSUs will vest in eight equal quarterly installments starting October 29, 2026, increasing his direct holdings to 154,866 Class A Common Stock shares. This transaction, reported via a Form 4 filing, is a grant and does not involve any stock sales by the CFO.
Tempus AI (TEM) CEO-affiliated entities sell 250K shares under 10b5-1 plan
Entities affiliated with Tempus AI (TEM) CEO and Chairman Eric P. Lefkofsky sold 250,000 shares of Class A Common Stock on July 28, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted March 8, 2026, at weighted-average prices between $40.79 and $43.13 per share. Despite these transactions totaling $10.51 million, Lefkofsky retains significant direct and indirect holdings in the company.
Tempus AI CEO Eric Lefkofsky sells $10.5m in shares
Tempus AI CEO Eric Lefkofsky sold approximately $10.5 million worth of shares through various entities on July 28, 2026, as part of a Rule 10b5-1 trading plan. The shares were sold at prices ranging from $41.34 to $42.95, while the stock currently trades at $44.29 and has experienced significant volatility. InvestingPro analysis suggests the stock is overvalued, despite recent news of narrower-than-expected losses and increased revenue.
Tempus AI, Inc. Class A (TEM) Q3 2024 Earnings Report - Results, Call & Slides
Tempus AI, Inc. Class A (TEM) has released its Q3 2024 earnings report, showing an EPS of -$4.36 which beat the consensus estimate of -$4.64. The company also reported actual revenue of $3.15 billion, exceeding the expected $3.13 billion. The earnings call was held on Monday, November 4, 2024, after close.
Tempus AI, Inc. Class A (TEM) Q1 2025 Earnings Report - Results, Call & Slides
Tempus AI, Inc. Class A (TEM) reported its Q1 2025 earnings, beating analyst expectations for both EPS and revenue. The company posted an actual EPS of -$4.18 against a consensus of -$4.53, and actual revenue of $4.46 billion compared to an expected $4.33 billion. The earnings announcement took place on May 6, 2025, after close.
Tempus AI, Inc. Class A (TEM) Q4 2024 Earnings Report - Results, Call & Slides
Tempus AI, Inc. (TEM) released its Q4 2024 earnings report, showing a miss on both EPS and revenue expectations. The company reported an actual EPS of -$3.12 against a consensus of -$2.71, and actual revenue of $3.48 billion against an expected $3.52 billion. The next earnings date for Tempus AI, Inc. Class A is estimated for November 10, 2026.
Tempus AI Posts Strong Q2 Results, Raises 2026 Outlook
Tempus AI (TEM) reported strong second-quarter 2026 results with revenue up 22% year-over-year to $382.5 million and gross profit up 26%, driven by growth in oncology diagnostics and data licensing. The company achieved GAAP net income and improved adjusted EBITDA, while also announcing the acquisition of Personalis for $1.5 billion and securing FDA approval for its xT CDx assay. Consequently, Tempus AI raised its full-year 2026 revenue guidance to $1.595–$1.605 billion and expects about $65 million in adjusted EBITDA.
Tempus AI (NASDAQ: TEM) holder files to sell 250,000 Class A shares
Eric Lefkofsky and affiliated entities have filed a Form 144 to sell up to 250,000 shares of Tempus AI Class A common stock, valued at $10,727,500. This filing also details previous sales by Lefkofsky, Blue Media, LLC, and Gray Media, LLC over the past three months. The shares for the proposed sale were initially acquired through stock compensation, direct cash investments, and a donation.
Weekly Recap: All-stock buyout capped 0.3356 and OneOme national PGx
Tempus AI (TEM) is expanding its precision medicine footprint. The company has rolled out its OneOme pharmacogenomics panel nationally, offering 27-gene tests with rapid results. Additionally, Tempus AI plans to acquire another company in an all-stock deal, capped at 0.3356, with an option for up to 50% cash, expected to close in late 2026 to early 2027.
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Brainsway (BWAY) and Argenx Se (ARGX)
This article highlights bullish analyst ratings for three healthcare companies: Tempus AI, Inc. Class A (TEM), Brainsway (BWAY), and Argenx Se (ARGX). H.C. Wainwright analysts reiterated Buy ratings for all three, with price targets of $64.00 for Tempus AI, $17.00 for Brainsway, and $940.00 for Argenx Se, indicating potential upsides based on consensus ratings.
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Brainsway (BWAY) and Argenx Se (ARGX)
This article highlights bullish sentiments from financial analysts on three healthcare companies: Tempus AI, Inc. Class A (TEM), Brainsway (BWAY), and Argenx Se (ARGX). H.C. Wainwright analysts reiterated Buy ratings and set price targets for all three, with other firms also maintaining or initiating Buy ratings, indicating expected upside for these stocks.
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM)
This article provides an overview of recent analyst ratings for two healthcare companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM). Bank of America Securities maintained a Buy rating on 4D Molecular Therapeutics, citing a strong upside potential. William Blair assigned a Hold rating to Tempus AI, Inc. Class A, while Bank of America Securities also maintained a Hold rating for TEM.
Tempus AI buys Personalis for $1.5 billion
Tempus AI has agreed to acquire Personalis for $1.5 billion, or $16.25 per share, to integrate Personalis' cancer-monitoring technology into its precision-oncology platform. The deal, which allows Tempus to pay up to 50% in cash, is anticipated to close in late 2026 or early 2027. This acquisition aims to capitalize on the growing market for minimal residual disease (MRD) monitoring in cancer patients.
ETFs Investing in Tempus AI, Inc. Class A Stocks
This article lists various ETFs that currently hold Tempus AI, Inc. Class A stocks, sorted by market value. It provides key details for each ETF, such as their market value, weight of Tempus AI stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The ETFs highlighted range from broad market funds to more specialized thematic funds like those focusing on innovation, artificial intelligence, and biotechnology.
Tempus AI Announces Acquisition of Personalis, Inc. in Definitive Merger Agreement
Tempus AI, Inc. has entered into a definitive agreement to acquire Personalis, Inc. The acquisition will involve an exchange of Personalis shares for Tempus Class A common stock and cash, pending approval from Personalis stockholders and regulatory clearances. This transaction will result in Personalis becoming a wholly-owned subsidiary of Tempus AI, with further details on the terms and conditions to be provided in upcoming SEC filings.
Tempus AI (TEM) plans stock-plus-cash merger with Personalis (PSNL)
Tempus AI (TEM) has agreed to acquire Personalis (PSNL) in a two-step stock-plus-cash merger deal. Personalis shareholders will receive primarily Tempus Class A common stock, with Tempus retaining the option to pay up to 50% in cash, while ensuring at least 40% of the total consideration is in stock for tax-free reorganization treatment. The transaction, valued at approximately $76.8 million in termination fees, is subject to Personalis stockholder approval, regulatory clearances, and the effectiveness of an S-4 registration statement.
Tempus AI (NASDAQ: TEM) plans $1.5B all-stock acquisition of Personalis
Tempus AI (NASDAQ: TEM) announced its intention to acquire Personalis, Inc. (NASDAQ: PSNL) in an all-stock transaction valued at $1.5 billion, or $16.25 per share. This strategic acquisition, building on an existing collaboration, aims to integrate Personalis' tumor-informed minimal residual disease (MRD) technology with Tempus' AI-enabled precision oncology platform to enhance cancer monitoring and accelerate insights. The deal is expected to close in late 2026 or early 2027, pending shareholder and regulatory approvals, and will expand Tempus’ capabilities in the rapidly growing $20 billion MRD market.
Tempus AI Announces Definitive Agreement to Acquire Personalis in Strategic All-Stock Merger Enhancing AI-Driven Oncology and Genomic Testing Capabilities
Tempus AI, Inc. announced a definitive merger agreement to acquire Personalis, Inc., a genomic data and AI company specializing in cancer genomics. This all-stock merger aims to integrate Personalis's oncology-focused genomic testing and data capabilities with Tempus's AI-driven clinical intelligence platform. The acquisition signifies a major consolidation within the precision oncology and healthcare AI sectors, bringing together complementary technologies and data assets.
Tempus AI, Inc. Class A (TEM) Q3 2025 Earnings Report - Results, Call & Slides
Tempus AI, Inc. (TEM) announced its Q3 2025 earnings, reporting an EPS of -$0.11, beating the consensus estimate of -$0.17. The company's revenue reached $334.21 million, surpassing the expected $328.70 million and showing an 84.72% year-over-year growth. The next earnings report is estimated for July 30, 2026.
Tempus AI, Inc. Class A (TEM) Q3 2024 Earnings Report - Results, Call & Slides
Tempus AI, Inc. (TEM) has released its Q3 2024 earnings report, showing an actual EPS of -$0.25, beating the consensus of -$0.27 by $0.02. The company also reported actual revenue of $180.93 million, exceeding the expected revenue of $179.52 million. This report includes details on their earnings call, slide deck, and historical earnings data, with the next earnings date estimated for July 30, 2026.
Tempus AI, Inc. Class A (TEM) Q1 2025 Earnings Report - Results, Call & Slides
Tempus AI, Inc. (TEM) released its Q1 2025 earnings report, exceeding analyst expectations. The company reported Actual EPS of -$0.24, beating the consensus of -$0.26 by $0.02, and Actual Revenue of $255.74M, surpassing the expected $248.13M by $7.61M. The next earnings date is estimated for July 30, 2026.
